Zacks: Analysts Anticipate BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Will Post Quarterly Sales of $25.10 Million

Equities analysts predict that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will report sales of $25.10 million for the current fiscal quarter, Zacks reports. Five analysts have made estimates for BioDelivery Sciences International’s earnings. The lowest sales estimate is $23.99 million and the highest is $27.30 million. BioDelivery Sciences International reported sales of $12.18 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 106.1%. The company is scheduled to report its next earnings report on Thursday, August 8th.

According to Zacks, analysts expect that BioDelivery Sciences International will report full year sales of $101.51 million for the current fiscal year, with estimates ranging from $97.66 million to $107.25 million. For the next fiscal year, analysts forecast that the company will report sales of $145.36 million, with estimates ranging from $135.60 million to $153.34 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for BioDelivery Sciences International.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.03. BioDelivery Sciences International had a negative net margin of 42.09% and a negative return on equity of 43.40%. The company had revenue of $19.77 million for the quarter, compared to analyst estimates of $19.60 million.



BDSI has been the topic of a number of analyst reports. BidaskClub cut shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. Cantor Fitzgerald reiterated a “buy” rating on shares of BioDelivery Sciences International in a report on Friday, March 8th. Zacks Investment Research raised shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Tuesday, May 21st. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of BioDelivery Sciences International in a report on Friday, March 15th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $6.20.

NASDAQ:BDSI traded down $0.05 during trading hours on Friday, hitting $4.30. 20,517 shares of the stock traded hands, compared to its average volume of 743,186. The company has a current ratio of 2.88, a quick ratio of 2.57 and a debt-to-equity ratio of 1.90. BioDelivery Sciences International has a 1 year low of $2.35 and a 1 year high of $5.37. The stock has a market capitalization of $392.95 million, a P/E ratio of -5.90 and a beta of 0.47. The firm has a 50 day moving average of $4.50.

In other news, Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $5.19, for a total value of $41,520.00. Following the completion of the transaction, the director now owns 606,254 shares in the company, valued at approximately $3,146,458.26. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Herm Cukier sold 30,285 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $5.07, for a total value of $153,544.95. Following the completion of the sale, the chief executive officer now directly owns 66,666 shares in the company, valued at approximately $337,996.62. The disclosure for this sale can be found here. Insiders have sold 4,339,037 shares of company stock worth $21,313,438 over the last quarter. 8.94% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Emerald Advisers LLC boosted its position in BioDelivery Sciences International by 881.4% during the first quarter. Emerald Advisers LLC now owns 1,734,422 shares of the specialty pharmaceutical company’s stock valued at $9,192,000 after purchasing an additional 1,557,692 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its position in BioDelivery Sciences International by 836.4% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 1,556,947 shares of the specialty pharmaceutical company’s stock worth $8,252,000 after acquiring an additional 1,390,682 shares during the last quarter. Nantahala Capital Management LLC grew its position in BioDelivery Sciences International by 64.0% during the 4th quarter. Nantahala Capital Management LLC now owns 2,733,567 shares of the specialty pharmaceutical company’s stock worth $10,114,000 after acquiring an additional 1,066,900 shares during the last quarter. Millennium Management LLC lifted its holdings in BioDelivery Sciences International by 703.6% during the 4th quarter. Millennium Management LLC now owns 981,422 shares of the specialty pharmaceutical company’s stock worth $3,631,000 after buying an additional 859,292 shares in the last quarter. Finally, Pura Vida Investments LLC acquired a new position in BioDelivery Sciences International during the 4th quarter worth $2,305,000. Institutional investors and hedge funds own 56.73% of the company’s stock.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Story: Understanding Market Liquidity

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.